Teva and Amgen latest to submit trastuzumab biosimilars to US FDA for review

The US FDA has accepted submission of two further Herceptin (trastuzumab) biosimilars: ABP 980 developed by Amgen and Allergan, and Teva and Celltrion’s CT-P6.
Back in January
, a tratsuzumab molecule developed by Indian drug firms Mylan and Biocon became the first biosimilar of Roche’s blockbuster anti-HER2 monoclonal antibody Herceptin to be accepted for review by the US Food and Drug Administration (FDA).
And last month
an FDA committee voted unanimously in favour of its approval, paving the way for the first Herceptin biosimilar to arrive in the US.
But while Mylan is looking to take a slice of a market which raked in CHF 2.5bn ($2.6bn) for Roche last year
, the firm may soon have to compete against a number of other competitors, including two more Herceptin biosimilars which were successfully submitted to the FDA for review this week: ABP980 and CT-P6.
ABP 980 is one of four oncology biosimilars being co-developed following a $400m collaboration inked in 2011 between Amgen and Allergan (then Watson Pharmaceuticals). The submission of the molecule is the second in the partnership to be sent to the FDA after a version of Avastin (bevacizumab) ABP 215 which has subsequently been recommended for approval.
The submission of CT-P6 meanwhile marks Teva’s first biosimilar breakthrough in the US after teaming up with Korean drugmaker Celltrion last October
. The Israeli generics giant holds the North American commercialisation rights for CT-P6 and CT-P10 – a version of another Roche blockbuster, Rituxan (rituximab) – following the deal, worth $160m.
“We look forward to the opportunity to leverage Teva’s strong legacy and US commercial presence in oncology to bring additional biosimilar treatment options to patients,” Paul Rittman, SVP at Teva Oncology said yesterday. “With today’s announcement, we are one-step closer to doing so in the US.”
Source:http://www.biosimilars.io/teva-and-amgen-latest-to-submit-trastuzumab-biosimilars-to-us-fda-for-review-biopharma-reporter-com/

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more